v3.26.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities      
Net income $ 11,286 $ 13,874 $ 16,635
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation 826 730 623
Amortization 2,126 2,065 5,692
Provision for losses on accounts receivable 367 (4) (33)
Amortization of operating lease assets 56 51 53
Deferred income taxes (659) (359) (693)
Stock-based compensation expense 373 256 225
Tax benefit attributable to exercise of stock options 0 21 12
Accounts receivable 338 (835) 2,270
Other receivables (5) 54 0
Inventories 1,195 587 (670)
Prepaid expenses and other current assets (54) (32) 45
Accounts payable 211 (73) (456)
Accrued expenses (1,368) (1,504) (1,422)
Net cash provided by operating activities 14,692 14,831 22,281
Cash flows from investing activities      
Property and equipment (371) (230) (639)
Intangible assets 0 (5) 0
Proceeds from the sale of property and equipment 0 27 0
Net cash (used in) investing activities (371) (208) (639)
Cash flows from financing activities      
Proceeds from issuance of common stock - options 0 390 117
Common stock purchased and retired (8,355) (19,968) 0
Dividends paid (3,983) (4,260) (4,282)
Net cash (used in) financing activities (12,338) (23,838) (4,165)
Effect of exchange rate changes on cash 797 (677) 339
Net increase (decrease) in cash and cash equivalents 2,780 (9,892) 17,816
Cash at beginning of year 82,976 92,868 75,052
Cash at end of year 85,756 82,976 92,868
Income taxes 4,003 4,638 4,827
Interest $ 0 $ 0 $ 0